Archford Capital Strategies LLC Has $2.02 Million Stake in Eli Lilly and Company (NYSE:LLY)

Archford Capital Strategies LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 41.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,447 shares of the company’s stock after selling 1,705 shares during the quarter. Archford Capital Strategies LLC’s holdings in Eli Lilly and Company were worth $2,021,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in LLY. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter worth about $48,000. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 53.3% in the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after buying an additional 24 shares in the last quarter. Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $63,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $792.41 on Thursday. The stock has a 50-day moving average price of $782.41 and a 200 day moving average price of $800.16. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm has a market cap of $751.00 billion, a price-to-earnings ratio of 64.48, a PEG ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, June 7th. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.